C |
Palbociclib – CDK-4/6 Inhibitor |
C2 |
ADC or NOS NSCLC |
p16 (CDKN2A) loss of function with proficient Rb |
|
|
C6 |
NSCLC |
KRAS mutation with proficient Rb
(No concomitant STK11/LKB1 mutation or deletion, no PIK3CA mutation or amplification, no PTEN mutation or homozygous deletion, no AKT mutation, no EGFR mutation, no FGFR2/3 mutation, no TSC1/2 mutation, and no HER2 mutation)
|
D |
Crizotinib – ALK Inhibitor |
D2 |
NSCLC |
ROS1 gene fusions |
F |
AZD5363 - AKT Inhibitor |
F1 |
SCC |
PIK3CA mutation & no KRAS, NF1, NRAS, HRAS or BRAF aberrations |
|
|
F2 |
SCC |
PIK3CA amplification & no KRAS, NF1, NRAS, HRAS or BRAF aberrations |
|
|
F3 |
NSCLC |
PIK3CA mutation or PIK3CA amplification & no KRAS, NF1, NRAS, HRAS or BRAF aberrations (ADC or NOS NSCLC)
PTEN mutation or PTEN loss & no KRAS, NF1, NRAS, HRAS or BRAF aberrations (ADC or NOS NSCLC)
AKT mutation & no KRAS, NF1, NRAS, HRAS or BRAF aberrations (NSCLC)
|
|
|
F4 |
SCC |
PTEN loss or PTEN mutation & no KRAS, NF1, NRAS, HRAS or BRAF aberrations |
G |
Osimertinib – EGFR mutation positive T790M+ Inhibitor |
G1 |
NSCLC |
EGFR mutation & T790M mutation |
H |
Sitravatinib – VEGFR inhibitor |
H1 |
NSCLC |
RET rearrangements |
NA |
Durvalumab – PD-L1 Inhibitor |
NA1 |
NSCLC |
No actionable genetic change for other trial arms |